早期剂量明确化试验在卒中后运动恢复中应用不足:一项系统范围综述
该范围综述系统检索MEDLINE和EMBASE,纳入41项行为运动干预的剂量明确化研究,涵盖临床前至IIB期。所有研究均采用单维度方法,时间是最常研究的维度(53%),仅65%报告剂量、45%报告安全性,61%存在高偏倚风险。结论强调需开展更多高质量、多维度剂量明确化的早期试验。
要点
- 行为运动卒中恢复的剂量研究多采用单维度设计,时间维度最常见。
- 仅65%研究报告剂量、45%报告安全性,61%存在高偏倚风险。
- 亟需投资改进早期试验设计(尤其I期)以支持多维度剂量明确化。
核心结论
- 行为运动卒中恢复领域需更多高质量、多维度剂量明确化的早期试验。
- 需投资改进早期试验设计尤其是I期以支持多维度剂量明确化。
研究设计与样本
- 系统范围综述,检索MEDLINE和EMBASE。
- 纳入41项研究:3项临床前剂量准备(93只啮齿类)、2项I期剂量范围(21名参与者)、9项IIA期剂量筛选(198名参与者)、27项IIB期剂量发现(1879名参与者)。
主要发现
- 所有研究均采用单维度方法。
- 时间是最常研究的维度(53%),其次为强度(29%)和安排(18%)。
- 95%研究报告疗效结局,但仅65%报告剂量、45%报告安全性。
- 61%研究存在高偏倚风险,干预描述和质量报告的平均百分比分别为61%和67%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To enable development of effective interventions, there is a need to complete systematic early-phase dose articulation research. This scoping review aimed to synthesize dose articulation research of behavioral motor interventions for stroke recovery. METHODS: MEDLINE and EMBASE were systematically searched for dose articulation studies. Preclinical experiments and adult clinical trials were classified based on the discovery pipeline and analyzed to determine which dose dimensions were articulated (time, scheduling or intensity) and how they were investigated (unidimensional vs multidimensional approach). Reporting of dose, safety and efficacy outcomes were summarized. The intervention description, risk of bias, and quality was appraised. RESULTS: We included 41 studies: 3 of preclinical dose preparation (93 rodents), 2 Phase I dose ranging (21 participants), 9 Phase IIA dose screening (198 participants), and 27 Phase IIB dose finding (1879 participants). All studies adopted a unidimensional approach. Time was the most frequent dimension investigated (53%), followed by intensity (29%), and scheduling (18%). Overall, 95% studies reported an efficacy outcome; however, only 65% reported dose and 45% reported safety. Across studies, 61% were at high risk of bias, and the average percentage reporting of intervention description and quality was 61% and 67%, respectively. CONCLUSION: This review highlights a need to undertake more high-quality, early-phase studies that systematically articulate intervention doses from a multidimensional perspective in the field of behavioral motor stroke recovery. To address this gap, we need to invest in adapting early phase trial designs, especially Phase I, to support multidimensional dose articulation.
引用
- Dalton EJ, Churilov L, Lannin NA, et al. Early-phase dose articulation trials are underutilized for post-stroke motor recovery: A systematic scoping review. Ann Phys Rehabil Med. 2021. PMID: 33429089. doi:10.1016/j.rehab.2021.101487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。